Trade Cyclerion Therapeutics, Inc. - CYCN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0444 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024262% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00204% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.5628 |
| Open | 3.4428 |
| 1-Year Change | 31.84% |
| Day's Range | 3.1028 - 3.4428 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 13, 2024 | 3.4128 | -0.0300 | -0.87% | 3.4428 | 3.4428 | 3.0928 |
| Dec 12, 2024 | 3.5628 | 0.0600 | 1.71% | 3.5028 | 3.6928 | 3.4428 |
| Dec 11, 2024 | 3.6828 | -0.6100 | -14.21% | 4.2928 | 4.3728 | 3.6128 |
| Dec 10, 2024 | 4.1528 | -0.1400 | -3.26% | 4.2928 | 5.1728 | 4.0528 |
| Dec 9, 2024 | 4.0428 | 0.3500 | 9.48% | 3.6928 | 4.8628 | 3.5928 |
| Dec 6, 2024 | 3.6028 | -1.6300 | -31.15% | 5.2328 | 5.4428 | 3.2528 |
| Dec 5, 2024 | 5.2828 | 0.6200 | 13.30% | 4.6628 | 5.6128 | 4.5228 |
| Dec 4, 2024 | 6.0728 | 0.9700 | 19.01% | 5.1028 | 9.3928 | 4.6428 |
| Dec 3, 2024 | 1.5928 | -0.5500 | -25.67% | 2.1428 | 2.2028 | 1.5228 |
| Dec 2, 2024 | 2.3328 | 0.1800 | 8.36% | 2.1528 | 2.3628 | 2.0928 |
| Nov 29, 2024 | 2.2028 | 0.0900 | 4.26% | 2.1128 | 2.3028 | 2.0228 |
| Nov 27, 2024 | 2.1128 | -0.0300 | -1.40% | 2.1428 | 2.3128 | 1.7128 |
| Nov 26, 2024 | 1.3528 | -0.0400 | -2.87% | 1.3928 | 1.4028 | 1.2828 |
| Nov 25, 2024 | 1.4428 | -0.0500 | -3.35% | 1.4928 | 1.5328 | 1.4228 |
| Nov 22, 2024 | 1.4028 | -0.0100 | -0.71% | 1.4128 | 1.4828 | 1.2528 |
| Nov 21, 2024 | 1.5128 | -0.3200 | -17.46% | 1.8328 | 1.9528 | 1.4228 |
| Nov 20, 2024 | 2.0428 | 0.2800 | 15.88% | 1.7628 | 2.2528 | 1.7628 |
| Nov 19, 2024 | 1.7528 | -0.3600 | -17.04% | 2.1128 | 2.1928 | 1.7128 |
| Nov 18, 2024 | 2.0828 | -0.1200 | -5.45% | 2.2028 | 2.5028 | 1.9928 |
| Nov 15, 2024 | 2.5228 | 0.7800 | 44.76% | 1.7428 | 2.9328 | 1.7028 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cyclerion Therapeutics, Inc. Company profile
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cyclerion Therapeutics Inc revenues increased 72% to $3.9M. Net loss decreased 34% to $51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 32% to $33.7M (expense), General & Administrative - Balancing decrease of 27% to $15M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
301 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com